Iron Deficiency Injectable Industry Analysis Report: Key Trends, Drivers, and Forecast Insights

 Ideal for market intelligence professionals and business strategists, this research uncovers where growth is headed in the iron deficiency injectable industry.

 

 How Large Will The Iron Deficiency Injectable Market Be By 2025?
 The iron deficiency injectable market size has grown strongly in recent years. It will grow from $14.06 billion in 2024 to $15.22 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to high prevalence of iron deficiency anemia treatments, bariatric surgery patients, pediatric and adolescent patients, growing pregnancy.
 
 The iron deficiency injectable market size is expected to see rapid growth in the next few years. It will grow to $22.81 billion in 2029 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to geriatric population, global health initiatives, government initiatives, incresing treatments for chronic conditions, rapid iron replenishment. Major trends in the forecast period include advances in iron formulations, digital health solutions, advancements in iron deficiency injectable therapy, adoption of iron-based drugs.
 
 Get your free sample today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=12907&type=smp
 
 What Are Key Factors Driving The Demand In The Global Iron Deficiency Injectable Market?
 The increasing prevalence of polycystic ovary syndrome (PCOS) is expected to propel the growth of the iron deficiency injectables market going forward. Polycystic ovary syndrome (PCOS) is a common hormonal disorder that affects people with ovaries, primarily women of reproductive age. Polycystic ovary syndrome (PCOS) leads to iron overload, which results in excessive blood loss during menstruation and makes patients anemic, which can be cured by injectable iron deficiency medications. For instance, in June 2023, according to the World Health Organization, a US-based specialized health agency, globally, polycystic ovary syndrome (PCOS) affects an estimated 8–13% of reproductive-aged women, among whom 70% remain undiagnosed. Therefore, the prevalence Of polycystic ovary syndrome (PCOS) is driving the growth of the iron deficiency injectables market.
 
 Comparative Analysis Of Leading Iron Deficiency Injectable Market Segments
 The iron deficiency injectablemarket covered in this report is segmented — 
 
 1) By Type: Iron Dextran; Iron Sucrose; Ferric Carboxymaltose
 2) By Branded or Generics: Branded; Generics
 3) By Application: Chronic Kidney Disease; Inflammatory Bowel Disease; Cancer; Other Applications
 4) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
 
 Subsegments:
 1) By Iron Dextran: Low Molecular Weight Iron Dextran; High Molecular Weight Iron Dextran
 2) By Iron Sucrose: Venofer
 3) By Ferric Carboxymaltose: Injectafer; Ferinject
 
 What Are The Key Trends Shaping The Iron Deficiency Injectable Industry?
 Major companies operating in the iron deficiency injectables market are developing new therapies, such as INJECTAFER, to sustain their position in the market. For instance, in June 2023, Daiichi Sankyo Company, a US-based healthcare company and American Regent Inc., a US-based injectables manufacturer, launched INJECTAFER (ferric carboxymaltose injection) for iron deficiency, which the Food And Drug Administration, a US-based government agency, approved. This is the first and only intravenous iron replacement therapy for adult patients with chronic and progressive heart failure to receive FDA approval. More than 40 clinical trials involving more than 8,800 participants from different countries were examined with INJECTAFER. This latest approval builds on INJECTAFER’s successful and demonstrated use in these patients, including adult and pediatric patients with iron-deficient anemia and heart failure.
 
 Who Are The Prominent Players In The Iron Deficiency Injectable Business?
 Major companies operating in the iron deficiency injectable market are Daiichi Sankyo Company Limited, Pfizer Inc., Aetna Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A, AstraZeneca PLC, GSK PLC, Fresenius Medical Care, Teva Pharmaceutical Industries Ltd., Mylan N.V., B Braun Medical Inc., Sandoz, Fresenius Kabi AG, Cipla Limited, Emcure Pharmaceuticals Ltd., AMAG Pharmaceuticals Inc., Luitpold Pharmaceuticals Inc., Akebia Therapeutics Inc., Covis Pharma GmbH, Keryx Biopharmaceuticals Inc., Rockwell Medical Inc., American Regent Inc., Galen Medical Group.
 
 View the full iron deficiency injectable market report here:
 https://www.thebusinessresearchcompany.com/report/iron-deficiency-injectable-global-market-report
 
 Which Region Is Expected To Lead The Iron Deficiency Injectable Market By 2025?
 North America was the largest region in the iron deficiency injectable market in 2024. The regions covered in iron deficiency injectable market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company